metoprolol has been researched along with Left Ventricular Dysfunction in 82 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effects of antihypertensive treatment on subclinical left ventricular dysfunction and to compare the effects of nebivolol with metoprolol." | 9.15 | Reversal of subclinical left ventricular dysfunction by antihypertensive treatment: a prospective trial of nebivolol against metoprolol. ( Cinteza, M; Ciobanu, AO; Dragoi, R; Dulgheru, R; Fraser, AG; Gherghinescu, C; Lautaru, A; Magda, S; Niculescu, N; Vinereanu, D, 2011) |
| "In patients with depressed < or =35% ejection fraction after acute myocardial infarction treatment with low doses of metoprolol, bisoprolol and cardvediolol did not reduce mortality rate in 24-month observation." | 9.12 | [Effect of low doses of metoprolol, bisoprolol and carvedilol on mortality in patients with left ventricular dysfunction after acute myocardial infarction]. ( Chizyński, K; Goch, JH; Maciejewski, M; Ptaszyński, P; Ruta, J, 2006) |
| "Carvedilol has previously been demonstrated to be beneficial in patients with acute myocardial infarction (AMI) and left ventricular (LV) dysfunction." | 9.12 | Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction. ( Asanin, MR; Jelena, MM; Lasica, RM; Matic, MD; Mrdovic, IB; Ostojic, MC; Perunicic, JP; Savic, LZ; Vasiljevic, ZM, 2007) |
| "Metoprolol CR/XL once daily in addition to standard therapy improved both diastolic and systolic function in patients with chronic heart failure and decreased ejection fraction." | 9.11 | Metoprolol CR/XL improves systolic and diastolic left ventricular function in patients with chronic heart failure. ( Frøland, G; Gullestad, L; Hole, T; Offstad, J; Skjaerpe, T, 2004) |
| "The Carvedilol or Metoprolol European Trial (COMET) compared the effects of a comprehensive adrenergic antagonist, carvedilol (target dosage 25 mg twice daily), with a beta-1-selective agent, metoprolol tartrate (target dosage 50 mg twice daily), in 3029 patients with chronic heart failure caused by left ventricular systolic dysfunction." | 9.11 | Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET. ( Cleland, JG, 2004) |
| "The pre-treatment plasma level of ANP may be a predictor of LV antiremodelling from treatment with metoprolol in patients with chronic heart failure." | 9.10 | Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure. ( Fritz-Hansen, T; Groenning, BA; Hildebrandt, PR; Kjaer, A; Larsson, HB; Nilsson, JC; Sondergaard, L, 2002) |
| "MERIT-HF (Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure) was a randomized, placebo-controlled study, the purpose of which was to evaluate the effect of metoprolol controlled-release/extended-release (CR/XL) in 3991 patients with New York Heart Association class II to IV heart failure and LVEF < or =0." | 9.10 | Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). ( Deedwania, PC; Ghali, JK; Gottlieb, SS; Piña, IL; Wikstrand, JC, 2002) |
| "Carvedilol is a beta-adrenergic antagonist with vasodilatory properties (alpha1-antagonism), which has been extensively evaluated in the treatment of patients with heart failure." | 8.84 | Carvedilol: use in chronic heart failure. ( Doughty, RN; White, HD, 2007) |
| "Compare heart rate control between parenteral metoprolol and diltiazem and identify safety outcomes in the acute management of atrial fibrillation (AFib) with rapid ventricular response (RVR) in patients with heart failure with reduced ejection fraction (HFrEF)." | 8.31 | Acute rate control with metoprolol versus diltiazem in atrial fibrillation with heart failure with reduced ejection fraction. ( Allison-Aipa, T; Choi, M; Kapustova, K; Phan, B, 2023) |
| "Acute intravenous infusion of ranolazine (Ran), an anti-ischemic/antiangina drug, was previously shown to improve left ventricular (LV) ejection fraction (EF) without a concomitant increase in myocardial oxygen consumption in dogs with chronic heart failure (HF)." | 7.74 | Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. ( Belardinelli, L; Blackburn, B; Gupta, RC; Mishra, S; Rastogi, S; Sabbah, HN; Sharov, VG; Stanley, WC, 2008) |
| "Since chagasic patients with severe congestive heart failure have left ventricular systolic dysfunction and neurohormonal activation, we administered metoprolol to nine chagasic patients who were in severe congestive heart failure." | 7.71 | Effects of metoprolol in chagasic patients with severe congestive heart failure. ( Angel, F; Arata de Bellabarba, G; Dávila, DF; Donis, JH, 2002) |
| "We evaluated acute hemodynamic effects of metoprolol +/- nitroglycerin in 11 patients with left ventricular dysfunction and biopsy-proven lymphocytic myocarditis." | 7.70 | Acute hemodynamic effects of metoprolol +/- nitroglycerin in patients with biopsy-proven lymphocytic myocarditis. ( Bojić, M; Mirić, M; Popović, AD; Popović, Z; Sagić, D; Vasiljević, J, 1998) |
| " As a single, yet important adverse event, the reversible deterioration of walking abilities of one DMD patient during the run-in period was observed." | 6.90 | Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial. ( Dittrich, S; Ebinger, F; Graf, E; Heilmann, A; Khalil, M; Kirschner, J; Korenke, C; Lange, M; Motz, R; Müller-Felber, W; Neudorf, U; Pattathu, J; Pozza, RD; Schara, U; Schröder, R; Stiller, B; Trollmann, R; von Au, K; von der Hagen, M; Weiss, K; Wiechmann, N; Wilichowski, E, 2019) |
| "Thirty consecutive DCM patients with persistent LV dysfunction (ejection fraction < or =40%) and reduced exercise tolerance (peak oxygen consumption <25 ml/kg/min) despite chronic (>1 year) tailored treatment with metoprolol and angiotensin-converting enzyme inhibitors were enrolled in a 12-month, open-label, parallel trial and were randomized either to continue on metoprolol (n = 16, mean dosage 142+/-44 mg/day) or to cross over to maximum tolerated dosage of carvedilol (n = 14, mean dosage 74+/-23 mg/day)." | 6.69 | Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. ( Camerini, F; Ciani, F; Di Lenarda, A; Gregori, D; Klugmann, S; Mestroni, L; Muzzi, A; Pinamonti, B; Sabbadini, G; Salvatore, L; Sinagra, G, 1999) |
| "Transient Left Ventricular Apical Ballooning Syndrome (TLVABS) has been described to occur in response to number of stressful events, drug effects or drug withdrawal." | 5.35 | Transient left ventricular apical ballooning syndrome caused by abrupt metoprolol withdrawal. ( Boguszewski, A; Jefic, D; Koul, D; Martini, W, 2008) |
| " The aim of this study was to assess: (1) longitudinal change in circulating cardiovascular biomarkers, (2) the effect of metoprolol succinate and candesartan cilexetil on the biomarker response, and (3) the associations between on-treatment changes in biomarker concentrations and subsequent left ventricular dysfunction in patients with early breast cancer receiving anthracyclines." | 5.24 | Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study. ( Geisler, J; Gravdehaug, B; Gulati, G; Hagve, TA; Heck, SL; Hoffmann, P; Norseth, J; Omland, T; Ree, AH; Røsjø, H; Steine, K, 2017) |
| "To assess the effects of antihypertensive treatment on subclinical left ventricular dysfunction and to compare the effects of nebivolol with metoprolol." | 5.15 | Reversal of subclinical left ventricular dysfunction by antihypertensive treatment: a prospective trial of nebivolol against metoprolol. ( Cinteza, M; Ciobanu, AO; Dragoi, R; Dulgheru, R; Fraser, AG; Gherghinescu, C; Lautaru, A; Magda, S; Niculescu, N; Vinereanu, D, 2011) |
| "Carvedilol has previously been demonstrated to be beneficial in patients with acute myocardial infarction (AMI) and left ventricular (LV) dysfunction." | 5.12 | Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction. ( Asanin, MR; Jelena, MM; Lasica, RM; Matic, MD; Mrdovic, IB; Ostojic, MC; Perunicic, JP; Savic, LZ; Vasiljevic, ZM, 2007) |
| "In patients with depressed < or =35% ejection fraction after acute myocardial infarction treatment with low doses of metoprolol, bisoprolol and cardvediolol did not reduce mortality rate in 24-month observation." | 5.12 | [Effect of low doses of metoprolol, bisoprolol and carvedilol on mortality in patients with left ventricular dysfunction after acute myocardial infarction]. ( Chizyński, K; Goch, JH; Maciejewski, M; Ptaszyński, P; Ruta, J, 2006) |
| "Metoprolol CR/XL once daily in addition to standard therapy improved both diastolic and systolic function in patients with chronic heart failure and decreased ejection fraction." | 5.11 | Metoprolol CR/XL improves systolic and diastolic left ventricular function in patients with chronic heart failure. ( Frøland, G; Gullestad, L; Hole, T; Offstad, J; Skjaerpe, T, 2004) |
| "The Carvedilol or Metoprolol European Trial (COMET) compared the effects of a comprehensive adrenergic antagonist, carvedilol (target dosage 25 mg twice daily), with a beta-1-selective agent, metoprolol tartrate (target dosage 50 mg twice daily), in 3029 patients with chronic heart failure caused by left ventricular systolic dysfunction." | 5.11 | Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET. ( Cleland, JG, 2004) |
| "The pre-treatment plasma level of ANP may be a predictor of LV antiremodelling from treatment with metoprolol in patients with chronic heart failure." | 5.10 | Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure. ( Fritz-Hansen, T; Groenning, BA; Hildebrandt, PR; Kjaer, A; Larsson, HB; Nilsson, JC; Sondergaard, L, 2002) |
| "MERIT-HF (Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure) was a randomized, placebo-controlled study, the purpose of which was to evaluate the effect of metoprolol controlled-release/extended-release (CR/XL) in 3991 patients with New York Heart Association class II to IV heart failure and LVEF < or =0." | 5.10 | Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). ( Deedwania, PC; Ghali, JK; Gottlieb, SS; Piña, IL; Wikstrand, JC, 2002) |
| " Studies investigating any of three beta blockers (carvedilol, bisoprolol, and extended release metoprolol succinate) which are known to be effective in adult patients with heart failure were included." | 4.91 | Effects of beta-blockers for congestive heart failure in pediatric and congenital heart disease patients: a meta-analysis of published studies. ( Cho, MJ; Jung Kwak, M; Kim, HY; Kim, YM; Lee, HD; Lim, RK; Park, KH, 2015) |
| "Carvedilol is a beta-adrenergic antagonist with vasodilatory properties (alpha1-antagonism), which has been extensively evaluated in the treatment of patients with heart failure." | 4.84 | Carvedilol: use in chronic heart failure. ( Doughty, RN; White, HD, 2007) |
| "Compare heart rate control between parenteral metoprolol and diltiazem and identify safety outcomes in the acute management of atrial fibrillation (AFib) with rapid ventricular response (RVR) in patients with heart failure with reduced ejection fraction (HFrEF)." | 4.31 | Acute rate control with metoprolol versus diltiazem in atrial fibrillation with heart failure with reduced ejection fraction. ( Allison-Aipa, T; Choi, M; Kapustova, K; Phan, B, 2023) |
| "To investigate whether heart rate reduction via I(f)-channel blockade and β-receptor blockade prevents left ventricular (LV) dysfunction, we studied ivabradine and metoprolol in angiotensin II-induced heart failure." | 3.78 | Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade. ( Becher, PM; Lindner, D; Miteva, K; Savvatis, K; Schmack, B; Schultheiss, HP; Tschöpe, C; Van Linthout, S; Westermann, D; Zietsch, C, 2012) |
| "Acute intravenous infusion of ranolazine (Ran), an anti-ischemic/antiangina drug, was previously shown to improve left ventricular (LV) ejection fraction (EF) without a concomitant increase in myocardial oxygen consumption in dogs with chronic heart failure (HF)." | 3.74 | Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. ( Belardinelli, L; Blackburn, B; Gupta, RC; Mishra, S; Rastogi, S; Sabbah, HN; Sharov, VG; Stanley, WC, 2008) |
| "Twenty-two patients with heart failure were investigated at rest and during dobutamine stress echocardiography (DSE), before and after 6 months of metoprolol treatment." | 3.74 | The function of left ventricular basal segments is most important for long-term recovery. ( Andersson, B; Scharin Täng, M; Waagstein, F, 2007) |
| "We investigated the change of LV remodeling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 mg/kg/d) or metoprolol (60 mg/kg/d) treatment for 6 weeks (n = 9 in the MI plus carvedilol group, and n = 8 in every other group)." | 3.73 | Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. ( Hu, SJ; Hu, Y; Sun, YL; Wang, LH; Zhou, JY, 2005) |
| " This study evaluates the effects of moxonidine and metoprolol on cardiac hemodynamics and survival in ADR-induced left ventricular dysfunction (total dose of 20 mg/kg in a 4-week regimen)." | 3.72 | Cardiovascular and survival effects of sympatho-inhibitors in adriamycin-induced cardiomyopathy in rats. ( Bellmont, S; Christen, MO; La Roche, B; Monassier, L; Thomas, L, 2004) |
| "Baroreflex sensitivity was assessed in 287 patients with history of myocardial infarction and left ventricular ejection fraction < or =40% by phenylephrine test and was found to be depressed (4." | 3.72 | [Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. ( Bozhko, AA; Kanopskiĭ, SG; Staritskiĭ, AG, 2004) |
| "Since chagasic patients with severe congestive heart failure have left ventricular systolic dysfunction and neurohormonal activation, we administered metoprolol to nine chagasic patients who were in severe congestive heart failure." | 3.71 | Effects of metoprolol in chagasic patients with severe congestive heart failure. ( Angel, F; Arata de Bellabarba, G; Dávila, DF; Donis, JH, 2002) |
| "We evaluated acute hemodynamic effects of metoprolol +/- nitroglycerin in 11 patients with left ventricular dysfunction and biopsy-proven lymphocytic myocarditis." | 3.70 | Acute hemodynamic effects of metoprolol +/- nitroglycerin in patients with biopsy-proven lymphocytic myocarditis. ( Bojić, M; Mirić, M; Popović, AD; Popović, Z; Sagić, D; Vasiljević, J, 1998) |
| "We administered oral metoprolol or no therapy to rats for 12 weeks after large myocardial infarction and subsequently examined left ventricular (LV) remodeling; myocardial tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 expression; and NO." | 3.70 | beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. ( Chandrasekar, B; Freeman, GL; Murray, DR; Prabhu, SD, 2000) |
| "Treatment with metoprolol was associated with more negative LS values of the apical segment (-2." | 3.30 | Metoprolol Improves Left Ventricular Longitudinal Strain at Rest and during Exercise in Obstructive Hypertrophic Cardiomyopathy. ( Andersen, MJ; Dybro, AM; Jensen, MK; Nielsen, RR; Pedersen, ALD; Poulsen, SH; Rasmussen, TB, 2023) |
| " As a single, yet important adverse event, the reversible deterioration of walking abilities of one DMD patient during the run-in period was observed." | 2.90 | Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial. ( Dittrich, S; Ebinger, F; Graf, E; Heilmann, A; Khalil, M; Kirschner, J; Korenke, C; Lange, M; Motz, R; Müller-Felber, W; Neudorf, U; Pattathu, J; Pozza, RD; Schara, U; Schröder, R; Stiller, B; Trollmann, R; von Au, K; von der Hagen, M; Weiss, K; Wiechmann, N; Wilichowski, E, 2019) |
| "Beta-blocker therapy can ameliorate left ventricular remodeling in asymptomatic patients with left ventricular systolic dysfunction." | 2.73 | Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. ( Adams, KF; Armstrong, WF; Colucci, WS; Ghali, JK; Gottlieb, SS; Greenberg, B; Klibaner, MI; Kolias, TJ; Kukin, ML; Sugg, JE, 2007) |
| "Treatment with carvedilol compared with metoprolol offers additional benefits among patients with atrial fibrillation." | 2.71 | Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. ( Charlesworth, A; Cleland, J; Hanrath, P; Komajda, M; Metra, M; Olsson, LG; Poole-Wilson, P; Swedberg, K; Torp-Pedersen, C, 2005) |
| "Beta-blockers substantially improve survival in patients with chronic heart failure (HF) with left ventricular systolic dysfunction, but concerns about cardiovascular adverse effects may deter physicians from prescribing this therapy." | 2.71 | Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. ( Coffey, CS; Curtis, JP; Foody, JM; Hebert, PR; Ko, DT; Krumholz, HM; Sedrakyan, A, 2004) |
| "Carvedilol treatment can improve cardiac function, symptoms, and cardiac sympathetic nerve activity in patients with DCM to a similar extent as metoprolol treatment." | 2.71 | Efficacy of carvedilol treatment on cardiac function and cardiac sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with metoprolol therapy. ( Adachi, H; Hoshizaki, H; Isobe, N; Naito, S; Oshima, S; Seki, R; Taniguchi, K; Toyama, T, 2003) |
| "Thirty consecutive DCM patients with persistent LV dysfunction (ejection fraction < or =40%) and reduced exercise tolerance (peak oxygen consumption <25 ml/kg/min) despite chronic (>1 year) tailored treatment with metoprolol and angiotensin-converting enzyme inhibitors were enrolled in a 12-month, open-label, parallel trial and were randomized either to continue on metoprolol (n = 16, mean dosage 142+/-44 mg/day) or to cross over to maximum tolerated dosage of carvedilol (n = 14, mean dosage 74+/-23 mg/day)." | 2.69 | Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. ( Camerini, F; Ciani, F; Di Lenarda, A; Gregori, D; Klugmann, S; Mestroni, L; Muzzi, A; Pinamonti, B; Sabbadini, G; Salvatore, L; Sinagra, G, 1999) |
| "Enoximone was given at a dose of < or = 1 mg/kg body weight three times a day." | 2.69 | Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. ( Abraham, WT; Bristow, MR; Ferguson, DA; Gilbert, EM; Lowes, BD; Robertson, AD; Shakar, SF; Zisman, LS, 1998) |
| " Furthermore, the dosing of metoprolol tartrate in COMET may have been inadequate based on prior studies." | 2.42 | Pharmacokinetics and pharmacodynamics of beta blockers in heart failure. ( Talbert, RL, 2004) |
| " We analyze the problems with the trial design of COMET from the standpoint of comparing 2 therapeutic agents at different positions on a common dose-response curve, and discuss the theoretical reasons why postjunctional adrenergic receptor blockade that is in addition to beta1-receptor antagonism will likely produce only minimal or no incremental benefit in chronic heart failure." | 2.42 | Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? ( Adams, KF; Bristow, MR; Feldman, AM; Goldstein, S, 2003) |
| " To date, controlled clinical trials performed in more than 13,000 patients with chronic heart failure have consistently shown that the long term administration of beta-blockers is associated with significant improvement in left ventricular function, clinical symptoms, and survival." | 2.41 | [Role of beta-blockers in the treatment of chronic heart heart failure]. ( Czuriga, I; Edes, I, 2001) |
| "A metoprolol therapy was established, however to resistant tachycardia, we suggested a combined therapy of Bisoprolol and Ivabradin, which resulted successfully in normocard sinus rhythm." | 1.40 | [A heart without overspeed trip unit]. ( Gähwiler, R; Ghadri, JR; Lüscher, TF; Templin, C, 2014) |
| "Transient Left Ventricular Apical Ballooning Syndrome (TLVABS) has been described to occur in response to number of stressful events, drug effects or drug withdrawal." | 1.35 | Transient left ventricular apical ballooning syndrome caused by abrupt metoprolol withdrawal. ( Boguszewski, A; Jefic, D; Koul, D; Martini, W, 2008) |
| "Metoprolol treatment tended to normalize LV end-diastolic pressure (LVEDP)." | 1.30 | Comparative efficacy of a DA2/alpha2 agonist and a beta-blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion. ( Bernasconi, R; Bongrani, S; Calvillo, L; Fiordaliso, F; Jeremic, G; Latini, R; Luvarà, G; Masson, S; Razzetti, R; Rondelli, I; Torri, M, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (8.54) | 18.2507 |
| 2000's | 57 (69.51) | 29.6817 |
| 2010's | 15 (18.29) | 24.3611 |
| 2020's | 3 (3.66) | 2.80 |
| Authors | Studies |
|---|---|
| Bogush, N | 1 |
| Tan, L | 1 |
| Naqvi, E | 1 |
| Calvert, JW | 1 |
| Graham, RM | 1 |
| Taylor, WR | 1 |
| Naqvi, N | 1 |
| Husain, A | 1 |
| Dybro, AM | 3 |
| Rasmussen, TB | 3 |
| Nielsen, RR | 3 |
| Pedersen, ALD | 3 |
| Andersen, MJ | 3 |
| Jensen, MK | 3 |
| Poulsen, SH | 3 |
| Kapustova, K | 1 |
| Phan, B | 1 |
| Allison-Aipa, T | 1 |
| Choi, M | 1 |
| Gulati, G | 1 |
| Heck, SL | 1 |
| Røsjø, H | 1 |
| Ree, AH | 1 |
| Hoffmann, P | 1 |
| Hagve, TA | 1 |
| Norseth, J | 1 |
| Gravdehaug, B | 1 |
| Steine, K | 1 |
| Geisler, J | 1 |
| Omland, T | 1 |
| Sönmez, BM | 1 |
| İşcanlı, MD | 1 |
| Durdu, T | 1 |
| Kala, İ | 1 |
| Tarhan, N | 1 |
| Uysal, P | 1 |
| Calzadilla, A | 1 |
| Badiye, A | 1 |
| Ghodsizad, A | 1 |
| Bernstein, J | 1 |
| Campos, M | 1 |
| Mirsaeidi, M | 1 |
| Dittrich, S | 1 |
| Graf, E | 1 |
| Trollmann, R | 1 |
| Neudorf, U | 1 |
| Schara, U | 1 |
| Heilmann, A | 1 |
| von der Hagen, M | 1 |
| Stiller, B | 1 |
| Kirschner, J | 1 |
| Pozza, RD | 1 |
| Müller-Felber, W | 1 |
| Weiss, K | 1 |
| von Au, K | 1 |
| Khalil, M | 1 |
| Motz, R | 1 |
| Korenke, C | 1 |
| Lange, M | 1 |
| Wilichowski, E | 1 |
| Pattathu, J | 1 |
| Ebinger, F | 1 |
| Wiechmann, N | 1 |
| Schröder, R | 1 |
| Fonarow, G | 1 |
| Kaya, MG | 1 |
| Sarli, B | 1 |
| Akpek, M | 1 |
| Kaya, EG | 1 |
| Yarlioglues, M | 1 |
| Topsakal, R | 1 |
| Lam, YY | 1 |
| Gähwiler, R | 1 |
| Templin, C | 1 |
| Lüscher, TF | 1 |
| Ghadri, JR | 1 |
| Cho, MJ | 1 |
| Lim, RK | 1 |
| Jung Kwak, M | 1 |
| Park, KH | 1 |
| Kim, HY | 1 |
| Kim, YM | 1 |
| Lee, HD | 1 |
| Rastogi, S | 2 |
| Sharov, VG | 3 |
| Mishra, S | 2 |
| Gupta, RC | 2 |
| Blackburn, B | 1 |
| Belardinelli, L | 1 |
| Stanley, WC | 2 |
| Sabbah, HN | 3 |
| Kobayashi, M | 2 |
| Machida, N | 2 |
| Tanaka, R | 1 |
| Yamane, Y | 2 |
| Ulu, N | 1 |
| Henning, RH | 1 |
| Goris, M | 1 |
| Schoemaker, RG | 1 |
| van Gilst, WH | 1 |
| Allen LaPointe, NM | 1 |
| Zhou, Y | 1 |
| Stafford, JA | 1 |
| Hernandez, AF | 1 |
| Kramer, JM | 1 |
| Anstrom, KJ | 1 |
| Adams, KF | 3 |
| Fasullo, S | 1 |
| Cannizzaro, S | 1 |
| Maringhini, G | 1 |
| Ganci, F | 1 |
| Giambanco, F | 1 |
| Vitale, G | 1 |
| Pinto, V | 1 |
| Migliore, G | 1 |
| Torres, D | 1 |
| Sarullo, FM | 1 |
| Paterna, S | 1 |
| Di Pasquale, P | 1 |
| Remme, WJ | 1 |
| Vinereanu, D | 1 |
| Gherghinescu, C | 1 |
| Ciobanu, AO | 1 |
| Magda, S | 1 |
| Niculescu, N | 1 |
| Dulgheru, R | 1 |
| Dragoi, R | 1 |
| Lautaru, A | 1 |
| Cinteza, M | 1 |
| Fraser, AG | 1 |
| Lu, Y | 1 |
| Li, L | 1 |
| Zhao, X | 1 |
| Huang, W | 1 |
| Wen, W | 1 |
| Swiatkiewicz, I | 1 |
| Kozinski, M | 1 |
| Magielski, P | 1 |
| Gierach, J | 1 |
| Fabiszak, T | 1 |
| Kubica, A | 1 |
| Sukiennik, A | 1 |
| Navarese, EP | 1 |
| Odrowaz-Sypniewska, G | 1 |
| Kubica, J | 1 |
| Becher, PM | 1 |
| Lindner, D | 1 |
| Miteva, K | 1 |
| Savvatis, K | 1 |
| Zietsch, C | 1 |
| Schmack, B | 1 |
| Van Linthout, S | 1 |
| Westermann, D | 1 |
| Schultheiss, HP | 1 |
| Tschöpe, C | 1 |
| Ma, Y | 1 |
| Chilton, RJ | 1 |
| Lindsey, ML | 1 |
| Kezerashvili, A | 1 |
| Marzo, K | 1 |
| De Leon, J | 1 |
| Ishikura, F | 1 |
| Takano, Y | 1 |
| Ueyama, T | 1 |
| Williams, RV | 1 |
| Tani, LY | 1 |
| Shaddy, RE | 2 |
| Dávila, DF | 1 |
| Angel, F | 1 |
| Arata de Bellabarba, G | 1 |
| Donis, JH | 1 |
| Groenning, BA | 1 |
| Nilsson, JC | 1 |
| Hildebrandt, PR | 1 |
| Kjaer, A | 1 |
| Fritz-Hansen, T | 1 |
| Larsson, HB | 1 |
| Sondergaard, L | 1 |
| Metra, M | 2 |
| Nodari, S | 1 |
| Parrinello, G | 1 |
| Giubbini, R | 1 |
| Manca, C | 1 |
| Dei Cas, L | 1 |
| Morita, H | 1 |
| Suzuki, G | 1 |
| Mishima, T | 1 |
| Chaudhry, PA | 1 |
| Anagnostopoulos, PV | 1 |
| Tanhehco, EJ | 1 |
| Goldstein, S | 2 |
| Etheridge, SP | 1 |
| Taniguchi, Y | 1 |
| Ueshima, K | 1 |
| Chiba, I | 1 |
| Segawa, I | 1 |
| Kobayashi, N | 1 |
| Saito, M | 1 |
| Hiramori, K | 1 |
| Toyama, T | 1 |
| Hoshizaki, H | 1 |
| Seki, R | 1 |
| Isobe, N | 1 |
| Adachi, H | 1 |
| Naito, S | 1 |
| Oshima, S | 1 |
| Taniguchi, K | 1 |
| Massie, BM | 1 |
| Bristow, MR | 2 |
| Feldman, AM | 1 |
| Tabrizchi, R | 1 |
| Hole, T | 1 |
| Frøland, G | 1 |
| Gullestad, L | 1 |
| Offstad, J | 1 |
| Skjaerpe, T | 1 |
| Udelson, JE | 1 |
| Abdulla, J | 1 |
| Køber, L | 1 |
| Torp-Pedersen, C | 2 |
| Ko, DT | 1 |
| Hebert, PR | 1 |
| Coffey, CS | 1 |
| Curtis, JP | 1 |
| Foody, JM | 1 |
| Sedrakyan, A | 1 |
| Krumholz, HM | 1 |
| Kanopskiĭ, SG | 1 |
| Staritskiĭ, AG | 1 |
| Bozhko, AA | 1 |
| Talbert, RL | 1 |
| Thomas, L | 1 |
| Bellmont, S | 1 |
| Christen, MO | 1 |
| La Roche, B | 1 |
| Monassier, L | 1 |
| Mitsuishi, M | 1 |
| Swedberg, K | 1 |
| Olsson, LG | 1 |
| Charlesworth, A | 1 |
| Cleland, J | 1 |
| Hanrath, P | 1 |
| Komajda, M | 1 |
| Poole-Wilson, P | 1 |
| Tepliakov, AT | 1 |
| Kuznetsova, AV | 1 |
| Stepacheva, TA | 1 |
| D'iakova, ML | 1 |
| Shilov, SN | 1 |
| Bolotskaia, LA | 1 |
| Reiffel, JA | 1 |
| Cleland, JG | 1 |
| Sun, YL | 1 |
| Hu, SJ | 1 |
| Wang, LH | 1 |
| Hu, Y | 1 |
| Zhou, JY | 1 |
| Schröder, H | 1 |
| Tölg, R | 1 |
| Witt, M | 1 |
| Schwarz, B | 1 |
| Kurz, T | 1 |
| Kurowski, V | 1 |
| Hartmann, F | 1 |
| Geist, V | 1 |
| Richardt, G | 1 |
| Campos, LA | 1 |
| Iliescu, R | 1 |
| Fontes, MA | 1 |
| Schlegel, WP | 1 |
| Bader, M | 1 |
| Baltatu, OC | 1 |
| Doughty, RN | 1 |
| White, HD | 1 |
| Scharin Täng, M | 1 |
| Waagstein, F | 1 |
| Andersson, B | 1 |
| Schlosser, T | 1 |
| Mohrs, OK | 1 |
| Magedanz, A | 1 |
| Voigtländer, T | 1 |
| Schmermund, A | 1 |
| Barkhausen, J | 1 |
| Ruta, J | 1 |
| Ptaszyński, P | 1 |
| Maciejewski, M | 1 |
| Goch, JH | 1 |
| Chizyński, K | 1 |
| Heidenreich, PA | 1 |
| Gholami, P | 1 |
| Sahay, A | 1 |
| Massie, B | 1 |
| Goldstein, MK | 1 |
| Imai, M | 1 |
| Mika, Y | 1 |
| Rousso, B | 1 |
| Burkhoff, D | 1 |
| Ben-Haim, S | 1 |
| Colucci, WS | 1 |
| Kolias, TJ | 1 |
| Armstrong, WF | 1 |
| Ghali, JK | 2 |
| Gottlieb, SS | 2 |
| Greenberg, B | 1 |
| Klibaner, MI | 1 |
| Kukin, ML | 1 |
| Sugg, JE | 1 |
| Mrdovic, IB | 1 |
| Savic, LZ | 1 |
| Perunicic, JP | 1 |
| Asanin, MR | 1 |
| Lasica, RM | 1 |
| Jelena, MM | 1 |
| Matic, MD | 1 |
| Vasiljevic, ZM | 1 |
| Ostojic, MC | 1 |
| Chockalingam, A | 1 |
| Tejwani, L | 1 |
| Aggarwal, K | 1 |
| Dellsperger, KC | 1 |
| Fox, K | 1 |
| Borer, JS | 1 |
| Camm, AJ | 1 |
| Danchin, N | 1 |
| Ferrari, R | 1 |
| Lopez Sendon, JL | 1 |
| Steg, PG | 1 |
| Tardif, JC | 1 |
| Tavazzi, L | 1 |
| Tendera, M | 1 |
| Jefic, D | 1 |
| Koul, D | 1 |
| Boguszewski, A | 1 |
| Martini, W | 1 |
| Simões, MV | 1 |
| Marin-Neto, JA | 1 |
| Romano, MM | 1 |
| O'Connell, JL | 1 |
| de Santi, GL | 1 |
| Maciel, BC | 1 |
| Albert, NM | 1 |
| Bech, J | 1 |
| Madsen, JK | 1 |
| Kelbaek, H | 1 |
| Hvid-Jacobsen, K | 1 |
| Skagen, K | 1 |
| Popović, Z | 1 |
| Mirić, M | 1 |
| Vasiljević, J | 1 |
| Sagić, D | 1 |
| Bojić, M | 1 |
| Popović, AD | 1 |
| Latini, R | 1 |
| Masson, S | 1 |
| Jeremic, G | 1 |
| Luvarà, G | 1 |
| Fiordaliso, F | 1 |
| Calvillo, L | 1 |
| Bernasconi, R | 1 |
| Torri, M | 1 |
| Rondelli, I | 1 |
| Razzetti, R | 1 |
| Bongrani, S | 1 |
| Shakar, SF | 1 |
| Abraham, WT | 1 |
| Gilbert, EM | 1 |
| Robertson, AD | 1 |
| Lowes, BD | 1 |
| Zisman, LS | 1 |
| Ferguson, DA | 1 |
| Di Lenarda, A | 1 |
| Sabbadini, G | 1 |
| Salvatore, L | 1 |
| Sinagra, G | 1 |
| Mestroni, L | 1 |
| Pinamonti, B | 1 |
| Gregori, D | 1 |
| Ciani, F | 1 |
| Muzzi, A | 1 |
| Klugmann, S | 1 |
| Camerini, F | 1 |
| Nikitin, NP | 1 |
| Alyavi, AL | 1 |
| Goloskokova, VY | 1 |
| McMurray, JJ | 1 |
| Prabhu, SD | 1 |
| Chandrasekar, B | 1 |
| Murray, DR | 1 |
| Freeman, GL | 1 |
| Frantz, RP | 1 |
| Beanlands, RS | 1 |
| Nahmias, C | 1 |
| Gordon, E | 1 |
| Coates, G | 1 |
| deKemp, R | 1 |
| Firnau, G | 1 |
| Fallen, E | 1 |
| Coutinho, J | 1 |
| Hara, Y | 1 |
| Hamada, M | 1 |
| Shigematsu, Y | 1 |
| Murakami, B | 1 |
| Hiwada, K | 1 |
| Czuriga, I | 1 |
| Edes, I | 1 |
| Tsuyuki, RT | 1 |
| McKelvie, RS | 1 |
| Arnold, JM | 1 |
| Barretto, AC | 1 |
| Carvalho, AC | 1 |
| Isaac, DL | 1 |
| Kitching, AD | 1 |
| Piegas, LS | 1 |
| Teo, KK | 1 |
| Yusuf, S | 1 |
| Zaglavara, T | 1 |
| Haaverstad, R | 1 |
| Cumberledge, B | 1 |
| Irvine, T | 1 |
| Karvounis, H | 1 |
| Parharidis, G | 1 |
| Louridas, G | 1 |
| Kenny, A | 1 |
| Piña, IL | 1 |
| Deedwania, PC | 1 |
| Wikstrand, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, 2x2 Factorial, Double Blind Trial of Candesartan and Metoprolol[NCT01434134] | Phase 2 | 130 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Effect of Ivabradine, Carvedilol or Their Combination in Patients With Heart Failure[NCT01178528] | Phase 3 | 121 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock (ES-FISH)[NCT03437369] | Phase 4 | 22 participants (Anticipated) | Interventional | 2018-05-31 | Not yet recruiting | ||
| Effects of NEbivolol on Subclinical Left Ventricular dYSfunction. A Comparative Study Against Metoprolol. The ENESYS Study. A Phase 3, Randomised, Parallel, Active-controlled, Open Label Study[NCT00942487] | Phase 3 | 60 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| A Randomised Trial to Assess Catheter Ablation Versus Rate-Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure[NCT00878384] | 52 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| Clinical Reminders in Test Reports to Improve Guideline Compliance[NCT00414401] | 1,500 participants (Anticipated) | Interventional | 2001-05-31 | Completed | |||
| Italian Registry on Cardiac Contractility Modulation Therapy[NCT04327323] | 200 participants (Anticipated) | Observational [Patient Registry] | 2019-09-01 | Recruiting | |||
| [NCT00038077] | Phase 3 | 300 participants | Interventional | 2001-08-31 | Completed | ||
| A Single Centre, Retrospective Cohort Study on Post Analysis on the Link Between the Clinical Heart Rate and Outcomes During PCI[NCT02351674] | 15,000 participants (Anticipated) | Observational | 2015-01-31 | Not yet recruiting | |||
| Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease[NCT01365286] | Phase 4 | 40 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Effects of Long Term Adaptive Servo Ventilation Therapy on Myocardial Energetics and Sympathetic Nerve Function in Heart Failure and Sleep Apnea. The AMEND Sub-study[NCT02116140] | 60 participants (Anticipated) | Interventional | 2012-07-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Distance measured at 6 minute walking test. The 6 minute walking test was performed according to standardised procedure at baseline, before inclusion (at least 1 week after baseline evaluation), and at the end of the study. Patients who had not done at least two tests in the past underwent two practice 6 minute walking tests at least 3 days apart. Results are expressed in terms of distance walked (metres). The test was supervised by a physical therapist.~Patients were asked to walk at their own maximal pace a 100 m long hospital corridor. At the beginning of the last (6th) minute of the test a standard phrase of encouragement was told. Patients were allowed to stop if signs or symptoms of significant distress occurred (dyspnea, angina), through they were instructed to resume walking as soon as possible." (NCT01178528)
Timeframe: 3 months
| Intervention | meters (Mean) |
|---|---|
| Ivabradine | 474.8 |
| Carvedilol | 435.7 |
| Carvedilol and Ivabradine | 453.1 |
Functional capacity was assessed by means of a cardiopulmonary exercise test with a bicycle ergometer with gas exchange monitoring (Vmax 29 C, SensorMedics). Peak oxygen consumption was defined as the maximal oxygen consumption (MVO2) observed during exercise. (NCT01178528)
Timeframe: 3 months
| Intervention | mL/Kg/min (Mean) |
|---|---|
| Ivabradine | 15.8 |
| Carvedilol | 12.9 |
| Carvedilol and Ivabradine | 14.7 |
"The 1994 NYHA Classification system is a measure of functional status. It was designed for clinical assessment of patients by physicians as NYHA class I, II, III, or IV, on the basis of patient's limitations in physical activities caused by cardiac symptoms.~Class I describes patients with cardiovascular disease (CVD) but without resulting limitation of physical activity. There is no objective evidence of CVD.~Class II describes patients with CVD resulting in slight limitation of physical activity. There is objective evidence of minimal CVD.~Class III describes patients with CVD resulting in marked limitation of physical activity. There is objective evidence of moderately severe CVD.~Class IV describes patients with CVD resulting in inability to carry on any physical activity without discomfort. There is objective evidence of severe CVD.~Here we report data on number of patients showing an improvement by at least one NYHA class according to treatment allocation." (NCT01178528)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Ivabradine | 30 |
| Carvedilol | 5 |
| Carvedilol and Ivabradine | 20 |
Quality of life (QoL) was evaluated using the Visual Analogue Scale (VAS) which is a global measurement of QoL, allowing a subjective assessment of the impact of the disease and treatment. Patients are asked to indicate their current state in a line from 0 (worst state) to 10 (best state), with higher values therefore representing a better outcome. (NCT01178528)
Timeframe: 3 months
| Intervention | units on a scale (Mean) |
|---|---|
| Ivabradine | 6.7 |
| Carvedilol | 4.1 |
| Carvedilol and Ivabradine | 6.1 |
17 reviews available for metoprolol and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Effects of beta-blockers for congestive heart failure in pediatric and congenital heart disease patients: a meta-analysis of published studies.
Topics: Adrenergic beta-Antagonists; Age Factors; Bisoprolol; Carbazoles; Carvedilol; Child; Heart Defects, | 2015 |
Beta-blockers in heart failure: how far have we progressed?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Contraindi | 2002 |
Beta blocker use after acute myocardial infarction in the patient with normal systolic function: when is it "ok" to discontinue?
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Contraindications; Humans; Metoprolol; Myocar | 2012 |
Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; E | 2003 |
Should beta-blockers form the cornerstone for the treatment of congestive heart failure?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Dose | 2003 |
Ventricular remodeling in heart failure and the effect of beta-blockade.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2004 |
Methods of assessing the functional status of patients with left ventricular systolic dysfunction in interventional studies: can brain natriuretic peptide measurement be used as surrogate for the traditional methods?
Topics: Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Carbazoles; Carvedilol; Clinical Trials as Top | 2004 |
Pharmacokinetics and pharmacodynamics of beta blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Heart Failure | 2004 |
Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme 2; Anti-Arrhythmia Agents; Carbazoles; Ca | 2005 |
Carvedilol: use in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Diabe | 2007 |
Dynamic left ventricular outflow tract obstruction in acute myocardial infarction with shock: cause, effect, and coincidence.
Topics: Adrenergic beta-Antagonists; Aged; Algorithms; Amiodarone; Cardiac Catheterization; Diagnosis, Diffe | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Switching to once-daily evidence-based [beta]-blockers in patients with systolic heart failure or left ventricular dysfunction after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Algorithms; Carbazoles; Carvedilol; Delayed-Action Preparations; Eviden | 2007 |
Major beta blocker mortality trials in chronic heart failure: a critical review.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Female; He | 1999 |
Beta blockade in patients with congestive heart failure. Why, who, and how.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Heart Failure; H | 2000 |
[Adrenergic beta inhibitors in heart insufficiency: which and when?].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2001 |
[Role of beta-blockers in the treatment of chronic heart heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Controlled Clinica | 2001 |
28 trials available for metoprolol and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Metoprolol Improves Left Ventricular Longitudinal Strain at Rest and during Exercise in Obstructive Hypertrophic Cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Hypertrophic; Echocardiography; Heart Ventricles; Human | 2023 |
Metoprolol Improves Left Ventricular Longitudinal Strain at Rest and during Exercise in Obstructive Hypertrophic Cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Hypertrophic; Echocardiography; Heart Ventricles; Human | 2023 |
Metoprolol Improves Left Ventricular Longitudinal Strain at Rest and during Exercise in Obstructive Hypertrophic Cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Hypertrophic; Echocardiography; Heart Ventricles; Human | 2023 |
Metoprolol Improves Left Ventricular Longitudinal Strain at Rest and during Exercise in Obstructive Hypertrophic Cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Hypertrophic; Echocardiography; Heart Ventricles; Human | 2023 |
Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Antibiotics, | 2017 |
Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardio | 2019 |
Evaluation of beta-blockers on left ventricular dyssynchrony and reverse remodeling in idiopathic dilated cardiomyopathy: A randomized trial of carvedilol and metoprolol.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Biomarkers; Carbazoles; Cardiomyopathy, Dilate | 2014 |
Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings.
Topics: Aged; Benzazepines; Double-Blind Method; Female; Follow-Up Studies; Humans; Ivabradine; Male; Metopr | 2009 |
Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings.
Topics: Aged; Benzazepines; Double-Blind Method; Female; Follow-Up Studies; Humans; Ivabradine; Male; Metopr | 2009 |
Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings.
Topics: Aged; Benzazepines; Double-Blind Method; Female; Follow-Up Studies; Humans; Ivabradine; Male; Metopr | 2009 |
Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings.
Topics: Aged; Benzazepines; Double-Blind Method; Female; Follow-Up Studies; Humans; Ivabradine; Male; Metopr | 2009 |
Reversal of subclinical left ventricular dysfunction by antihypertensive treatment: a prospective trial of nebivolol against metoprolol.
Topics: Adult; Benzopyrans; Electrocardiography; Ethanolamines; Female; Humans; Male; Metoprolol; Middle Age | 2011 |
Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Biological Factors; Biomarkers; Blood P | 2002 |
Efficacy of carvedilol treatment on cardiac function and cardiac sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with metoprolol therapy.
Topics: 3-Iodobenzylguanidine; Adrenergic Antagonists; Adult; Aged; Carbazoles; Cardiomyopathy, Dilated; Car | 2003 |
Metoprolol CR/XL improves systolic and diastolic left ventricular function in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Echocardiography; Female; Heart Failure; Humans; Male; Metoprolol | 2004 |
Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Bradycardia; Carbazoles; Carvedilol; Dizziness; Fatig | 2004 |
Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carbazoles; Carvedilol; Double-Blind Method; | 2005 |
[Antiischemic and metabolic effects of nebivolol and metaprolol CR/XL (betalok ZOK) in patients with postinfarction heart dysfunction].
Topics: Adrenergic beta-Antagonists; Benzopyrans; Blood Glucose; Coronary Angiography; Coronary Circulation; | 2005 |
Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme 2; Anti-Arrhythmia Agents; Carbazoles; Ca | 2005 |
Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Morbidity; M | 2004 |
Comparison of carvedilol and metoprolol in patients with acute myocardial infarction undergoing primary coronary intervention--the PASSAT Study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Carbazoles; Carve | 2006 |
[Effect of low doses of metoprolol, bisoprolol and carvedilol on mortality in patients with left ventricular dysfunction after acute myocardial infarction].
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aged; Angioplasty, Balloon, Coronary; Bisoprolol; | 2006 |
Clinical reminders attached to echocardiography reports of patients with reduced left ventricular ejection fraction increase use of beta-blockers: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Echocardiography; Electronic Mail; Humans | 2007 |
Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2007 |
Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cause of Death; Disease-Free Survival; Female; | 2007 |
Metoprolol abolishes exercise-induced left ventricular dysfunction in patients with silent ischemia.
Topics: Adrenergic beta-Antagonists; Cross-Over Studies; Double-Blind Method; Electrocardiography; Exercise; | 1996 |
Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Cardiotonic Agents; Drug Therapy, Combination; En | 1998 |
Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiomyopathy, D | 1999 |
Benefit of long-term treatment with metoprolol in patients with dilated cadiomyopathy receiving enalapril: focus on the pattern of left ventricular diastolic filling.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathy, Dilate | 1999 |
Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study.
Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Dilated; Delayed-Action Preparations; Dopamine; Double- | 2000 |
The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: A double-blind, placebo-controlled, positron-emission tomography study.
Topics: Acetates; Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbon Radioisotopes; Cardiomyopathies; | 2000 |
The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: A double-blind, placebo-controlled, positron-emission tomography study.
Topics: Acetates; Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbon Radioisotopes; Cardiomyopathies; | 2000 |
The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: A double-blind, placebo-controlled, positron-emission tomography study.
Topics: Acetates; Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbon Radioisotopes; Cardiomyopathies; | 2000 |
The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: A double-blind, placebo-controlled, positron-emission tomography study.
Topics: Acetates; Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbon Radioisotopes; Cardiomyopathies; | 2000 |
Beneficial effect of beta-adrenergic blockade on left ventricular function in haemodialysis patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atrial Natriuretic Factor; Female; Hemodynamics; Humans; M | 2001 |
Acute precipitants of congestive heart failure exacerbations.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Dise | 2001 |
Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF).
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Delayed-Action Preparat | 2002 |
38 other studies available for metoprolol and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Remuscularization with triiodothyronine and β
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Metoprolol; Mice; Myocardial Infarction; Myocardium | 2022 |
Acute rate control with metoprolol versus diltiazem in atrial fibrillation with heart failure with reduced ejection fraction.
Topics: Adult; Atrial Fibrillation; Cohort Studies; Diltiazem; Heart Failure; Heart Rate; Humans; Hypotensio | 2023 |
What's going wrong with this postpartum woman?
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Anticoagulants; Cardiomyopathies; Cardiovascular Agen | 2018 |
A Young Woman with Bradycardia and Hypotension.
Topics: Adrenergic beta-1 Receptor Antagonists; Analgesics, Opioid; Benzodiazepines; Bradycardia; Central Ne | 2018 |
Update on pharmacological advances.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Disea | 2004 |
[A heart without overspeed trip unit].
Topics: Adult; Algorithms; Benzazepines; Bisoprolol; Diagnosis, Differential; Drug Therapy, Combination; Ech | 2014 |
Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardio | 2008 |
Effects of beta-blocker on left ventricular remodeling in rats with volume overload cardiac failure.
Topics: Adrenergic beta-Antagonists; Animals; Echocardiography, Transesophageal; Heart Bypass, Right; Heart | 2008 |
Effects of ivabradine and metoprolol on cardiac angiogenesis and endothelial dysfunction in rats with heart failure.
Topics: Animals; Benzazepines; Heart Failure; Heart Rate; Ivabradine; Male; Metoprolol; Myocardial Infarctio | 2009 |
Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carb | 2009 |
Which beta-blocker is most effective in heart failure?
Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Clinical Tria | 2010 |
Beta blocker metoprolol protects against contractile dysfunction in rats after coronary microembolization by regulating expression of myocardial inflammatory cytokines.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Disease Models, Animal; Echocardiography; Embolism; | 2011 |
Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Antihypertensive Agents; Aspirin; Biom | 2012 |
Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II; Animals; Apoptosis; Benzazepines; Cyclic Nuc | 2012 |
Heart rate reduction: an old and novel candidate heart failure therapy.
Topics: Animals; Benzazepines; Heart Failure; Ivabradine; Male; Metoprolol; Tachycardia; Ventricular Dysfunc | 2012 |
Acute effects of beta-blocker with intrinsic sympathomimetic activity on stress-induced cardiac dysfunction in rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Celiprolol; Disease Mo | 2012 |
Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction.
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child, Preschool; Echocardio | 2002 |
Effects of metoprolol in chagasic patients with severe congestive heart failure.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Chagas Cardiomyopathy; Female; Heart Failure; Hum | 2002 |
Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Female; Follow-Up Stud | 2003 |
Effects of long-term monotherapy with metoprolol CR/XL on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Chronic Disease; Dogs; Female; Fibrosis; Heart Diseases; Heart | 2002 |
QT dispersion after beta-blocker therapy (carvedilol or metoprolol) in children with heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child Welfare; Child, Presch | 2003 |
A new method using pulmonary gas-exchange kinetics to evaluate efficacy of beta-blocking agents in patients with dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Cardiomyopathy, Dilated; Carteol | 2003 |
A comment on COMET: how to interpret a positive trial?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Europe; Heart | 2003 |
[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2004 |
Cardiovascular and survival effects of sympatho-inhibitors in adriamycin-induced cardiomyopathy in rats.
Topics: Adrenergic beta-Antagonists; Animals; Antibiotics, Antineoplastic; Dose-Response Relationship, Drug; | 2004 |
Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Disease Models, Animal; Echocardiography, Dopp | 2004 |
Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats.
Topics: Adrenergic beta-Antagonists; Animals; Calcium-Binding Proteins; Calcium-Transporting ATPases; Carbaz | 2005 |
[Antihypertensive therapy with left cardiac insufficiency].
Topics: Acebutolol; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Angiotensinogen; Animals; Animals, Geneticall | 2006 |
The function of left ventricular basal segments is most important for long-term recovery.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Echocardiography; Female; Heart Failure; Humans; | 2007 |
Assessment of left ventricular function and mass in patients undergoing computed tomography (CT) coronary angiography using 64-detector-row CT: comparison to magnetic resonance imaging.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Cardiac Output; Coronary Angiography; Female; | 2007 |
Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Defibrillators, Implantable; Disease Models, Animal; Dogs; Ele | 2007 |
Transient left ventricular apical ballooning syndrome caused by abrupt metoprolol withdrawal.
Topics: Cardiomyopathy, Hypertrophic; Female; Humans; Metoprolol; Middle Aged; Substance Withdrawal Syndrome | 2008 |
Transient left ventricular dysfunction due to stress-induced cardiomyopathy.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; | 2007 |
Acute hemodynamic effects of metoprolol +/- nitroglycerin in patients with biopsy-proven lymphocytic myocarditis.
Topics: Adrenergic beta-Antagonists; Adult; Drug Therapy, Combination; Female; Hemodynamics; Humans; Lymphoc | 1998 |
Comparative efficacy of a DA2/alpha2 agonist and a beta-blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Catechol | 1998 |
beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling.
Topics: Adrenergic beta-Antagonists; Animals; Cytokines; Gene Expression; Interleukin-1; Interleukin-6; Isop | 2000 |
Dobutamine stress echocardiography for the detection of myocardial viability in patients with left ventricular dysfunction taking beta blockers: accuracy and optimal dose.
Topics: Adrenergic beta-Antagonists; Atenolol; Cardiotonic Agents; Chronic Disease; Coronary Artery Bypass; | 2002 |